Connect Biopharma Holdings (CNTB) Common Equity (2020 - 2026)

Connect Biopharma Holdings has disclosed Common Equity across 7 years of filings, most recently posting $26.9 million for Q2 2026.

• In Q2 2026, Common Equity fell 62.35% year-over-year to $26.9 million; the TTM figure through Jun 2026 stood at $26.9 million (down 62.35% YoY), while the FY2025 annual figure was $42.0 million, down 54.45% from the prior year.
• Common Equity came in at $26.9 million for Q2 2026 at Connect Biopharma Holdings, down from $42.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $213.0 million in Q2 2022 to a low of $26.9 million in Q2 2026.
• Average Common Equity over 5 years is $94.0 million, with a median of $93.0 million recorded in 2024.
• Year-over-year, Common Equity retreated 9.19% in 2024 and tumbled 62.35% in 2026.
• Over 5 years, Common Equity stood at $154.2 million in 2022, then slumped by 34.19% to $101.5 million in 2023, then dropped by 9.19% to $92.2 million in 2024, then slumped by 54.45% to $42.0 million in 2025, then plunged by 36.01% to $26.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $26.9 million in Q2 2026, $42.6 million in Q1 2026, and $42.0 million in Q4 2025.